NASDAQ:MNKD

Mannkind Stock News

Healthcare > Biotechnology

Buy MNKD

*Your capital is at risk

$4.13

+0.240 (+6.17%)

At Close: Jul 24, 2026

MannKind Corporation to Present at the Piper Jaffray '–st Annual Healthcare Conference

12:00am, Friday, 29'th Nov 2019

MannKind Adds New Board Member - What It Means To Investors And Investor Activists

12:00am, Friday, 22'nd Nov 2019

Bruce & Co. Buys MannKind Corp, Sells Bunge

12:00am, Thursday, 14'th Nov 2019

MannKind Corporation 2019 Q3 - Results - Earnings Call Presentation

12:00am, Wednesday, 13'th Nov 2019

Teva Q3 profit misses estimates, tightens FY19 forecast | AlphaStreet

12:14pm, Thursday, 07'th Nov 2019

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported a wider loss in the third quarter of 2019. The bottom line missed analysts' expectations.

MannKind shares are trading lower after the company reported worse-than-expected Q3 sales results.

12:00am, Wednesday, 06'th Nov 2019

MannKind Reports Receives Second $12.5M Milestone Payment From United Therapeutics

12:00am, Monday, 04'th Nov 2019

The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

12:00am, Sunday, 03'rd Nov 2019

MannKind: Donde Esta Brasil - What Brazil Delay Means

12:00am, Monday, 28'th Oct 2019

MannKind- Conflicts And Misperception Over Bioavailability And The Correct Status For The Clinical Trial For Tre-T Has Created Self-Inflected Confusion.

12:00am, Wednesday, 16'th Oct 2019

MannKind shares are trading higher on above-average volume despite no company-specific news.

12:00am, Friday, 04'th Oct 2019

Mallinckrodt Option Alert: Nov 15 $4 Calls Sweep (11) near the Ask: 642 @ $0.4 vs 1 OI; Earnings 11/5 Before Open [est] Ref=$2.54

12:00am, Thursday, 03'rd Oct 2019

If MannKind Can Advance Its Pipeline During 2020, Traders Should Consider LEAPs

12:00am, Wednesday, 25'th Sep 2019

MannKind: Afrezza Scripts Flat, But Positive Events On Deck

12:00am, Sunday, 22'nd Sep 2019

MannKind Highlights Presentation Of Afrezza Clinical Data From Type 1 Diabetes Study At 55th Annual Meeting Of The EASD

12:00am, Thursday, 19'th Sep 2019

Mannkind Stock News

MannKind Corporation to Present at the Piper Jaffray '–st Annual Healthcare Conference

MannKind Adds New Board Member - What It Means To Investors And Investor Activists

Bruce & Co. Buys MannKind Corp, Sells Bunge

MannKind Corporation 2019 Q3 - Results - Earnings Call Presentation

Teva Q3 profit misses estimates, tightens FY19 forecast | AlphaStreet

MannKind shares are trading lower after the company reported worse-than-expected Q3 sales results.

MannKind Reports Receives Second $12.5M Milestone Payment From United Therapeutics

The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

MannKind: Donde Esta Brasil - What Brazil Delay Means

MannKind- Conflicts And Misperception Over Bioavailability And The Correct Status For The Clinical Trial For Tre-T Has Created Self-Inflected Confusion.

MannKind shares are trading higher on above-average volume despite no company-specific news.

Mallinckrodt Option Alert: Nov 15 $4 Calls Sweep (11) near the Ask: 642 @ $0.4 vs 1 OI; Earnings 11/5 Before Open [est] Ref=$2.54

If MannKind Can Advance Its Pipeline During 2020, Traders Should Consider LEAPs

MannKind: Afrezza Scripts Flat, But Positive Events On Deck

MannKind Highlights Presentation Of Afrezza Clinical Data From Type 1 Diabetes Study At 55th Annual Meeting Of The EASD

Top Fintech Company